|Articles|March 30, 2018

Thermo Fisher’s Krios G3i Cryo-Electron Microscope Announced as 2018 Edison Awards Finalist

The company’s Krios G3i cryo-electron microscope is a finalist in the 2018 Edison Awards.

Thermo Fisher Scientific announced on March 8, 2018 that its Krios G3i cryo-electron microscope (cryo-EM) is a finalist in the molecular analysis category for the 2018 Edison Awards. Award winners will be announced at the 31st Annual Edison Awards ceremony on Wednesday, April 11, 2018 in New York City.

"The Krios G3i is one of the most powerful, cryo-electron microscopes available commercially today," said Fitz De Smet, vice president, marketing, materials and structural analysis, Thermo Fisher Scientific, in a company press release. "Since the introduction of the first Krios in 2008, we have collaborated closely with leading researchers in both academia and industry to continuously improve performance and usability. In recent years, cryo-EM has revolutionized the world of structural biology and is also being quickly adopted by the pharmaceutical industry for drug research and development."

The microscope is used to study the molecular mechanisms of living systems. According to Thermo Fisher, understanding the molecular structure of proteins and viruses provides new insight into the mechanisms of disease processes and leads to better cures and drugs. The microscope was used in the work of three scientists whose developments were recognized by the 2017 Nobel Prize.

All nominations were reviewed by the Edison Awards Steering Committee; the final ballot was sent to an independent judging panel of more than 3000 professionals from the fields of product development, design, engineering, science, marketing, and education from a variety of industries and disciplines.

Source: Thermo Fisher Scientific


Related to this article

The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.